Traws Pharma Reports 2025 Results, Secures PIPE Financing

Traws Pharma ( (TRAW) ) has issued an announcement.

On April 15, 2026, Traws Pharma reported its full-year 2025 results and highlighted progress across its pipeline, led by tivoxavir marboxil (TXM) for influenza and ratutrelvir for COVID-19. The company is running a Phase 1 bridging study in Australia for a new once-monthly TXM tablet, preparing a single-dose human influenza challenge trial in the U.K. in the second quarter of 2026 pending MHRA approval, and working with the U.S. FDA to resolve a clinical hold on its TXM IND.

Traws also announced positive topline Phase 2a data for ratutrelvir from a 90-patient trial that showed proof-of-concept efficacy, including no viral rebounds versus PAXLOVID-eligible comparators and faster symptom resolution in PAXLOVID-ineligible patients, alongside a favorable safety profile. To support these programs, the company closed an up to $60 million PIPE financing on April 15, 2026, with $10 million upfront and the rest via milestone-based and three-year warrants, extending its cash runway into the first quarter of 2027 and positioning it to complete the planned TXM challenge trial and advance ratutrelvir’s development strategy.

Corporate developments during this period included the October 6, 2025 appointment of John Leaman, M.D., as an independent director, bringing finance and M&A expertise to the board. Leadership changes also saw the appointment of Iain Dukes, MA, DPhil, as chief executive officer, underscoring a focus on clinical execution, regulatory engagement, and capital allocation as Traws seeks to solidify its position in the antiviral therapeutics space.

The most recent analyst rating on (TRAW) stock is a Buy with a $6.50 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.

Spark’s Take on TRAW Stock

According to Spark, TipRanks’ AI Analyst, TRAW is a Neutral.

The score is held back primarily by weak financial performance (widening losses, rising cash burn, and negative equity), which elevates funding risk. Offsetting this are strong technical momentum (price above major moving averages with positive MACD) and multiple positive corporate catalysts tied to COVID and influenza pipeline progress, while valuation metrics are not supportive/meaningful given the loss-making profile.

To see Spark’s full report on TRAW stock, click here.

More about Traws Pharma

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel antiviral therapies targeting critical respiratory viral diseases. Its lead programs include tivoxavir marboxil (TXM) for influenza prophylaxis and treatment and ratutrelvir, a once-daily, ritonavir-independent oral Main protease inhibitor for acute COVID-19, aimed at both PAXLOVID-eligible and ineligible patients in large, multi-billion-dollar markets.

The company is pursuing opportunities in seasonal and pandemic influenza, including potential stockpiling and pandemic preparedness initiatives, and in COVID-19 treatment, particularly for high-risk patients with contraindications to existing regimens. Traws is also engaging with regulators in the U.S., U.K. and Australia to advance its clinical pipeline while strengthening its corporate governance with board and leadership appointments.

Average Trading Volume: 146,213

Technical Sentiment Signal: Strong Sell

Current Market Cap: $12.87M

See more data about TRAW stock on TipRanks’ Stock Analysis page.